caa a22 4500 44531415X CHVBK 20180317142640.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s11095-010-0195-6 doi (NATIONALLICENCE)springer-10.1007/s11095-010-0195-6 Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration [Elektronische Daten] [Alessandro Grattoni, Haifa Shen, Daniel Fine, Arturas Ziemys, Jaskaran Gill, Lee Hudson, Sharath Hosali, Randy Goodall, Xuewu Liu, Mauro Ferrari] ABSTRACT: Purpose: The purpose of this study is to demonstrate the long-term, controlled, zero-order release of low- and high-molecular weight chemotherapeutics through nanochannel membranes by exploiting the molecule-to-surface interactions presented by nanoconfinement. Methods: Silicon membranes were produced with nanochannels of 5, 13 and 20nm using standardized industrial microfabrication techniques. The study of the diffusion kinetics of interferonα-2b and leuprolide was performed by employing UV diffusion chambers. The released amount in the sink reservoir was monitored by UV absorbance. Results: Continuous zero-order release was demonstrated for interferonα-2b and leuprolide at release rates of 20 and 100μg/day, respectively. The release rates exhibited by these membranes were verified to be in ranges suitable for human therapeutic applications. Conclusions: Our membranes potentially represent a viable nanotechnological approach for the controlled administration of chemotherapeutics intended to improve the therapeutic efficacy of treatment and reduce many of the side effects associated with conventional drug administration. Springer Science+Business Media, LLC, 2010 chemotherapy nationallicence controlled release nationallicence drug delivery nationallicence implants nationallicence nanochannel nationallicence Grattoni Alessandro Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut Shen Haifa Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut Fine Daniel Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut Ziemys Arturas Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut Gill Jaskaran Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut Hudson Lee NanoMedical Systems, Inc., Austin, Texas, USA aut Hosali Sharath NanoMedical Systems, Inc., Austin, Texas, USA aut Goodall Randy NanoMedical Systems, Inc., Austin, Texas, USA aut Liu Xuewu Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut Ferrari Mauro Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 292-300 0724-8741 28:2<292 2011 28 11095 https://doi.org/10.1007/s11095-010-0195-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-010-0195-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Grattoni Alessandro Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut NATIONALLICENCE 700 1- Shen Haifa Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut NATIONALLICENCE 700 1- Fine Daniel Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut NATIONALLICENCE 700 1- Ziemys Arturas Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut NATIONALLICENCE 700 1- Gill Jaskaran Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut NATIONALLICENCE 700 1- Hudson Lee NanoMedical Systems, Inc., Austin, Texas, USA aut NATIONALLICENCE 700 1- Hosali Sharath NanoMedical Systems, Inc., Austin, Texas, USA aut NATIONALLICENCE 700 1- Goodall Randy NanoMedical Systems, Inc., Austin, Texas, USA aut NATIONALLICENCE 700 1- Liu Xuewu Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut NATIONALLICENCE 700 1- Ferrari Mauro Department of NanoMedicine and Biomedical Engineering (nBME), The University of Texas Medical School at Houston, Houston, Texas, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 292-300 0724-8741 28:2<292 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer